3 December 2018 - Amgen today announced the first clinical results from studies evaluating investigational novel bi-specific T cell engager (BiTE) immunotherapies AMG 420 and AMG 330. 

In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumour activity in patients with relapsed and/or refractory multiple myeloma and relapsed or refractory acute myeloid leukaemia, respectively. 

These data were highlighted during oral presentations at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.

Read Amgen press release